UMIN ID: UMIN000000719
Registered date:22/05/2007
Combination therapy of 5-Fluorouracil/gemcitabine/cisplatin for advanced hepatocellular carcinoma with extrahepatic metastases -A pilot study-
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Hepatocellular carcinoma with extrahepatic metastases |
| Date of first enrollment | 2007/05/07 |
| Target sample size | 5 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | The combination therapy of 5FU/gemcitabine/CDDP. Contunue the protocol as long as progression disease is observed. |
Outcome(s)
| Primary Outcome | Response for extrahepatic metastases |
|---|---|
| Secondary Outcome | Overall survival Safety |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 70years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | With other malignant disease. A pregnant woman, or a woman suspected of pregnancy. With severe infectious disease. With history of severe allergy. With severe renal function disease. With S-1. With severe allergy for 5FU, gemcitabine, or CDDP. With severe bone marrow supression. With pulmonary fibrosis. With the history of radiotharpy for lung. |
Related Information
| Primary Sponsor | Hiroshima University |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Hiroshima University |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kiminori Uka |
| Address | 1-2-3 Kasumi, Minami-ku, Hiroshima Japan |
| Telephone | |
| Affiliation | Hiroshima University Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Bio |
| scientific contact | |
| Name | Kazuaki Chayama |
| Address | 1-2-3 Kasumi, Minami-ku, Hiroshima Japan |
| Telephone | |
| Affiliation | Hiroshima University Department of Medicine and Molecular Science, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences |